ArticleRheumatology (Oxford, England)2010
The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.
Article in Rheumatology (Oxford, England), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed.
- Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).Annals of the rheumatic diseases · 2018Trial
- Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease: A Systematic Review and Network Meta-Analysis.Archives of rheumatology · 2025Article
- Monoclonal Antibodies in the Management of Inflammation in Wound Healing: An Updated Literature Review.Journal of clinical medicine · 2024Review
- Tocilizumab in the Treatment of Eosinophilic Fasciitis: A Case Study and Review of Literature.Mediterranean journal of rheumatology · 2023Review
- When natural antibodies become pathogenic: autoantibodies targeted against G protein-coupled receptors in the pathogenesis of systemic sclerosis.Frontiers in immunology · 2023Review
- Age-related mechanisms in the context of rheumatic disease.Nature reviews. Rheumatology · 2022Review
- Autoimmunity, cancer and COVID-19 abnormally activate wound healing pathways: critical role of inflammation.Histochemistry and cell biology · 2022Review
- Autoantibodies as Biomarker and Therapeutic Target in Systemic Sclerosis.Biomedicines · 2022Review
- Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review.Clinical reviews in allergy & immunology · 2022Review
- Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6?Biomedicines · 2022Review
- Role of B-Cell in the Pathogenesis of Systemic Sclerosis.Frontiers in immunology · 2022Review
- Problems to Consider Before Determining the Regimen of the Treatment for Juvenile Systemic Sclerosis Treatment: A Case Report Where Tocilizumab Monotherapy Succeeded Efficiently and Safely.Clinical medicine insights. Arthritis and musculoskeletal disorders · 2022Article
- Autoantibodies from Patients with Scleroderma Renal Crisis Promote PAR-1 Receptor Activation and IL-6 Production in Endothelial Cells.International journal of molecular sciences · 2021Article
- Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy.Cells · 2021Review
- Treatment of Calcinosis in Juvenile Dermatomyositis.Current rheumatology reports · 2021Review
- Lysyl oxidase directly contributes to extracellular matrix production and fibrosis in systemic sclerosis.American journal of physiology. Lung cellular and molecular physiology · 2021Article
- Current and Potential New Targets in Systemic Sclerosis Therapy: a New Hope.Current rheumatology reports · 2020Review
- Translating IL-6 biology into effective treatments.Nature reviews. Rheumatology · 2020Review
- Sildenafil Reduces Expression and Release of IL-6 and IL-8 Induced by Reactive Oxygen Species in Systemic Sclerosis Fibroblasts.International journal of molecular sciences · 2020Article
- Observational
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSSc is an autoimmune disease characterized by fibrosis of the skin and internal organs. Although the aetiology remains uncertain, many reports have suggested that IL-6 is involved in SSc pathogenesis. Tocilizumab, an anti-IL-6 receptor antibody, is an anti-arthritis medicine that works through the blockade of IL-6 functions. To examine the effect of tocilizumab on SSc, we administered tocilizumab to two SSc patients.
methodsTwo dcSSc patients were administered tocilizumab at 8 mg/kg once a month for 6 months. One patient had pulmonary fibrosis assessed by CT and spirometry, and the other had chronic renal failure caused by scleroderma renal crisis. Their skin condition was monitored with a Vesmeter and the modified Rodnan total skin score (mRTSS). Skin biopsies were obtained before and after the tocilizumab treatment to investigate the histological changes.
resultsAfter tocilizumab treatment, both patients showed softening of the skin with reductions of 50.7 and 55.7% in the total z-score of Vesmeter hardness and 51.9 and 23.0% in the mRTSS, respectively. Histological examination showed thinning of the collagen fibre bundles in the dermis. The creatinine clearance in the patient with chronic renal failure improved from 38 to 55 ml/min. However, the fibrotic changes in the lung in the other patient remained unchanged.
conclusionsIn the two cases of SSc that we report here, softening of the skin was observed during the treatment with tocilizumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.